Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: Targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Choi, Eun J ^a   Cho, Bong J ^a   Lee, David J ^a   Hwang, Yeo H ^a   Chun, Sun H ^a   Kim, Hans H ^a   Kim, In A ^a,b  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Glioblastoma; Pro survival signaling; Radiosensitization; Temozolomide

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; ALVESPIMYCIN; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE; MAMMALIAN TARGET OF RAPAMYCIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PANOBINOSTAT; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN; TEMOZOLOMIDE;

APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER RADIOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DNA REPAIR; DRUG POTENTIATION; DRUG TARGETING; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; GLIOBLASTOMA; HUMAN; HUMAN CELL; RADIOSENSITIZATION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; AUTOPHAGY; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CHEMORADIOTHERAPY; DACARBAZINE; DNA DAMAGE; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DOSE-RESPONSE RELATIONSHIP, RADIATION; EPIGENESIS, GENETIC; EPITHELIAL-MESENCHYMAL TRANSITION; GLIOMA; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HSP90 HEAT-SHOCK PROTEINS; HUMANS; NEOPLASM GRADING; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RADIATION-SENSITIZING AGENTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84892380757     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-17     Document Type: Article

References (42)

1. Stupp R, Hegi ME, Mason WP, Van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10(5):459-6 6. 10.1016/S1470-2045(09)70025-7, 19269895.
2. Cancer Genome Atlas Research Network Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455(7216):1061-1068. 10.1038/nature07385, 2671642, 18772890, Cancer Genome Atlas Research Network.
3. Lo HW. EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance. Curr Mol Pharmacol 2010, 3(1):37-52. 3606625, 20030624.
4. Quick A, Patel D, Hadziahmetovic M, Chakravarti A, Mehta M. Current therapeutic paradigms in glioblastoma. Rev Recent Clin Trials 2010, 5(1):14-27. 10.2174/157488710790820544, 20205684.
5. Bianco R, Shin I, Ritter CA, Yakes FM, Basso A, Rosen N, Tsurutani J, Dennis PA, Mills GB, Arteaga CL. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003, 22(18):2812-2822. 10.1038/sj.onc.1206388, 12743604.
6. Vivanco I, Rohle D, Versele M, Iwanami A, Kuga D, Oldrini B, Tanaka K, Dang J, Kubek S, Palaskas N, et al. The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proc Natl Acad Sci U S A 2010, 107(14):6459-6464. 10.1073/pnas.0911188107, 2851999, 20308550.
7. Choi EJ, Ryu YK, Kim SY, Wu HG, Kim JS, Kim IH, Kim IA. Targeting epidermal growth factor receptor-associated signaling pathways in non-small cell lung cancer cells: implication in radiation response. Mol Cancer Res 2010, 8(7):1027-1036. 10.1158/1541-7786.MCR-09-0507, 20587532.
8. Lavictoire SJ, Parolin DA, Klimowicz AC, Kelly JF, Lorimer IA. Interaction of Hsp90 with the nascent form of the mutant epidermal growth factor receptor EGFRvIII. J Biol Chem 2003, 278(7):5292-5299. 10.1074/jbc.M209494200, 12471035.
9. Kim IA, Bae SS, Fernandes A, Wu J, Muschel RJ, McKenna WG, Birnbaum MJ, Bernhard EJ. Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines. Cancer Res 2005, 65(17):7902-7910.
10. Arthur JC, Lich JD, Aziz RK, Kotb M, Ting JP. Heat shock protein 90 associates with monarch-1 and regulates its ability to promote degradation of NF-kappaB-inducing kinase. J Immunol 2007, 179(9):6291-6296.
11. Micallef J, Taccone M, Mukherjee J, Croul S, Busby J, Moran MF, Guha A. Epidermal growth factor receptor variant III-induced glioma invasion is mediated through myristoylated alanine-rich protein kinase C substrate overexpression. Cancer Res 2009, 69(19):7548-7556. 10.1158/0008-5472.CAN-08-4783, 19773446.
12. Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, Snyder EY, Sulman EP, Anne SL, Doetsch F, Colman H, et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 2010, 463(7279):318-325. 10.1038/nature08712, 20032975.
13. Liu XM, Zhang QP, Mu YG, Zhang XH, Sai K, Pang JC, Ng HK, Chen ZP. Clinical significance of vasculogenic mimicry in human gliomas. J Neurooncol 2011, 105(2):173-179. 10.1007/s11060-011-0578-5, 3198193, 21533525.
14. Hegi ME, Diserens AC, Gorlia T, Hamou MF, De Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352(10):997-1003. 10.1056/NEJMoa043331, 15758010.
15. Zhang S, Zhang D, Sun B. Vasculogenic mimicry: current status and future prospects. Cancer Lett 2007, 254(2):157-164. 10.1016/j.canlet.2006.12.036, 17306454.
16. Bigner SH, Humphrey PA, Wong AJ, Vogelstein B, Mark J, Friedman HS, Bigner DD. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res 1990, 50(24):8017-8022.
17. Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS, Vogelstein B. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 1992, 89(7):2965-2969. 10.1073/pnas.89.7.2965, 48784, 1557402.
18. Zhu H, Acquaviva J, Ramachandran P, Boskovitz A, Woolfenden S, Pfannl R, Bronson RT, Chen JW, Weissleder R, Housman DE, et al. Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis. Proc Natl Acad Sci U S A 2009, 106(8):2712-2716. 10.1073/pnas.0813314106, 2650331, 19196966.
19. Haas-Kogan DA, Prados MD, Tihan T, Eberhard DA, Jelluma N, Arvold ND, Baumber R, Lamborn KR, Kapadia A, Malec M, et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 2005, 97(12):880-887. 10.1093/jnci/dji161, 15956649.
20. Mellinghoff IK, Lassman AB, Wen PY. Signal transduction inhibitors and antiangiogenic therapies for malignant glioma. Glia 2011, 59(8):1205-1212. 10.1002/glia.21137, 21351155.
21. She QB, Solit D, Basso A, Moasser MM. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling. Clin Cancer Res 2003, 9(12):4340-4346.
22. Hu L, Zaloudek C, Mills GB, Gray J, Jaffe RB. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res 2000, 6(3):880-886.
23. Prasad G, Sottero T, Yang X, Mueller S, James CD, Weiss WA, Polley MY, Ozawa T, Berger MS, Aftab DT, et al. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro Oncol 2011, 13(4):384-392. 10.1093/neuonc/noq193, 3064692, 21317208.
24. Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 2008, 5(1):e8. 10.1371/journal.pmed.0050008, 2211560, 18215105.
25. Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, De Angelis L, Raizer J, et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 2005, 23(4):357-361. 10.1007/s10637-005-1444-0, 16012795.
26. Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, Peralba JM, Jenkins RB, Dakhil SR, Morton RF, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 2005, 23(23):5294-5304. 10.1200/JCO.2005.23.622, 15998902.
27. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 2010, 60(3):166-193. 10.3322/caac.20069, 2888474, 20445000.
28. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17(1):98-110. 10.1016/j.ccr.2009.12.020, 2818769, 20129251.
29. Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 1999, 91(22):1940-1949. 10.1093/jnci/91.22.1940, 10564678.
30. Tsutsumi S, Neckers L. Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis. Cancer Sci 2007, 98(10):1536-1539. 10.1111/j.1349-7006.2007.00561.x, 17645779.
31. Annamalai B, Liu X, Gopal U, Isaacs JS. Hsp90 is an essential regulator of EphA2 receptor stability and signaling: implications for cancer cell migration and metastasis. Mol Cancer Res 2009, 7(7):1021-1032. 10.1158/1541-7786.MCR-08-0582, 3155284, 19567782.
32. Dote H, Burgan WE, Camphausen K, Tofilon PJ. Inhibition of hsp90 compromises the DNA damage response to radiation. Cancer Res 2006, 66(18):9211-9220. 10.1158/0008-5472.CAN-06-2181, 16982765.
33. Gopal U, Bohonowych JE, Lema-Tome C, Liu A, Garrett-Mayer E, Wang B, Isaacs JS. A novel extracellular Hsp90 mediated co-receptor function for LRP1 regulates EphA2 dependent glioblastoma cell invasion. PloS One 2011, 6(3):e17649. 10.1371/journal.pone.0017649, 3050925, 21408136.
34. Wu N, Zhao X, Liu M, Liu H, Yao W, Zhang Y, Cao S, Lin X. Role of microRNA-26b in glioma development and its mediated regulation on EphA2. PloS One 2011, 6(1):e16264. 10.1371/journal.pone.0016264, 3021542, 21264258.
35. Powers MV, Workman P. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer 2006, 13(Suppl 1):S125-S135.
36. Baylin SB. Tying it all together: epigenetics, genetics, cell cycle, and cancer. Science 1997, 277(5334):1948-1949. 10.1126/science.277.5334.1948, 9333948.
37. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001, 1(3):194-202. 10.1038/35106079, 11902574.
38. Rosato RR, Grant S. Histone deacetylase inhibitors: insights into mechanisms of lethality. Expert Opin Ther Targets 2005, 9(4):809-824. 10.1517/14728222.9.4.809, 16083344.
39. Kim IA, No M, Lee JM, Shin JH, Oh JS, Choi EJ, Kim IH, Atadja P, Bernhard EJ. Epigenetic modulation of radiation response in human cancer cells with activated EGFR or HER-2 signaling: potential role of histone deacetylase 6. Radiother Oncol 2009, 92(1):125-132. 10.1016/j.radonc.2009.03.008, 19329208.
40. Qian DZ, Kato Y, Shabbeer S, Wei Y, Verheul HM, Salumbides B, Sanni T, Atadja P, Pili R. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res 2006, 12(2):634-642. 10.1158/1078-0432.CCR-05-1132, 16428510.
41. Geng L, Cuneo KC, Fu A, Tu T, Atadja PW, Hallahan DE. Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. Cancer Res 2006, 66(23):11298-11304. 10.1158/0008-5472.CAN-06-0049, 17145876.
42. Srivastava RK, Kurzrock R, Shankar S. MS-275 sensitizes TRAIL-resistant breast cancer cells inhibits angiogenesis and metastasis and reverses epithelial-mesenchymal transition in vivo. Mol Cancer Ther 2010, 9(12):3254-3266. 10.1158/1535-7163.MCT-10-0582, 21041383.